Scientific Program

Scientific Program

The latest updates by world-renowned experts in the field of diabetes

We are planning an innovative and exciting program for ATTD 2021. The full program will be available shortly.

Review the confirmed topics and speakers below.

*Updated 2 August, 2020

First NameLast NameCountryTopic
MichaelAbràmoffUSAAutonomous Artificial Intelligence and Diabetic Retinopathy: Safety, Efficacy and Equity
JeffreyAlfonsiCanadaTogether with Mark Palmert – iSpy: Novel Carbohydrate Counting Smartphone App for Youth with Type 1 Diabetes
StephanieAmielUKFrom Hesiod to Hollywood: getting the best blood glucose for rational thinking
KatharineBarnardUKTogether with Korey Hood: Patient Related Outcomes (PROs) – presentation of key instruments and how to use them (INSPIRE measures)
StephaneBidetFranceArtificial Intelligence applications to support decision management in insulin therapy
BruceBodeUSAManagement of glucose in the hospital using computerized systems
StefanBornsteinGermanyNovel medications for diabetes to be used during COVID-19 pandemic
CharlotteBoughtonUKBroadening usage of closed-loop
NatašaBratinaSloveniaImpact of patient reported outcomes on pediatric routine clinical work
BruceBuckinghamUSAA pivotal trial of Omnipod Horizon™ Automated Glucose Control System
FergusCameronAustraliaDebate: In the era of remote visits – do we still need A1c measures
Stuart Weinzimer – CON
Fergus Cameron – PRO
AntonioCerielloItalyHow to manage type 2 diabetes and obesity during the COVID-19 pandemic
PratikChoudharyUKTransplantation – managing partial pancreas function or managing the failing pancreas
MarkClementsUSAWhat do we need to develop/improve with the technology that we are using today
KellyCloseUSAHarnessing the power of social media and peer support
  • The SWEET project: benchmarking over 10 years is associated with improved HbA1c and increased use of diabetes technology in youth with type 1 diabetes worldwide
  • Ongoing clinical trials in INNODIA
ChristopheDe BlockBelgiumNAFLD/NASH in type 1 diabetes: overrated or underappreciated
HansDeVriesThe NetherlandsNew insulins: Foreseeable impact on diabetes therapy –
Once weekly insulins
  • Faster acting insulin analogues in closed-loop insulin delivery
  • Closed-loop and physical activity in youth with type 1 diabetes
FrancisDoyle IIIUSAUpdate on Artificial Pancreas engineering and clinical studies
DavidDungerUKInnovative trial design in INNODIA
StevenEdelmanUSAStrategies for improvement of metabolic control in adults with T1D
DeniceFeigCanadaDEBATE: Should all pregnant women with diabetes take metformin during pregnancy
Yariv Yogev – CON
Denice Feig – PRO
SatishGargUSAManaging T1D-new-onsets and DKA through telehealth
AhmadHaidarCanadamulti-hormone closed-loop systems
MichaelHallerUSAUsing tele-education with the ECHO model to reach primary care providers in rural areas to improve the level of care for people with diabetes
TimHeiseGermanyNew insulins: Foreseeable impact on diabetes therapy –
Smart Insulins
PauHerreroUKArtificial Intelligence upgrades automated insulin delivery towards a fully closed-loop
  • Lessons learned from the COVID-19 pandemic
  • How should reimbursement look after the COVID-19 pandemic
  • Insulin Affordability: will biosimilars help?
  • Leveraging telehealth and digital tools to optimize use of diabetes devices
  • Together with Katharine Barnard: Patient Related Outcomes (PROs) – presentation of key instruments and how to use them (INSPIRE measures)
RomanHovorkaUKUse of the CamAPS FX closed-loop in the research and clinical investigation
PeterJacobsUSADecision support and closed loop control during exercise:  new findings from clinical studies and larger data sets
ParthaKarUKWhere two worlds collide: how social media and peer support can enhance clinical care
BorisKovatchevUSAResults of a study on Closed-Loop Control (CLC) system – Control IQ
  • Patient preferences for automatic insulin delivery
  • Telemedicine for routine follow up type 1 diabetes pediatric visits
RobertLindsayUKFactors associated with stillbirth in women with diabetes
DavidMaahsUSANIH funded study: Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Pediatric T1D: 4T Study
ChantalMathieuBelgiumIntroduction INNODIA/INNODIA HARVEST study
LaurelMesserUSAArtificial pancreas device upgrades—best practices for onboarding and follow-up
OthmarMoserAustriaEASD/ISAP position statement on CGM/exercise in type 1 diabetes
HelenMurphyUKPregnancy outcomes of 17,375 women with diabetes: National population-based cohort study
OmarMustafaUKGlucose control during COVID-19 infection: targets and acute derangements
StevenNissenUSADual or triple GLP/GIPs as treatment for T2D
MarkPalmertCanadaTogether with Jeff Alfonsi – iSpy: Novel Carbohydrate Counting Smartphone App for Youth with Type 1 Diabetes
SusanaPattonUSAIntervening on Hypoglycemia Fear in Parents of Young Children using Direct-to-Home Video-based Telehealth
WilliamPolonskyUSAImpact of PROs on adult clinical care: why, when and how?
WalterPoriesUSAToxic Intestinal signals as a cause of type 2 diabetes and the metabolic syndrome
EricRenardFranceEfficacy of Closed-loop Insulin Therapy in Adults Prone to Hypoglycemia – the International Diabetes Closed-Loop Trial Protocol 2
MichaelRiddellCanadaMonitoring the elite athlete with type 1
FrancescoRubinoUKAn international register for new onset diabetes during COVID-19 pandemic
AndreaScaramuzzaItalyBenefits and challenges of diabetes technology in children
DesmondSchatzUSALessons from the nPOD
AnkeSchulteGermanyAn integrated search for novel biomarkers
EleanorScottUKWeek by week CGM profiles of pregnant women with type 1 diabetes
  • Diabetes Cardiovascular Outcome Trials – Current Status
  • Immunotherapy for type1 diabetes – Where are we now?
AmirTiroshIsraelVirtual Diabetes Clinic – the Dietitian Perspective
MariaVasiloglouSwitzerlandComparison of novel and traditional dietary assessment methods in diabetes patients
StuartWeinzimerUSADebate: In the era of remote visits – do we still need A1c measures
Fergus Cameron – PRO
Stuart Weinzimer – CON
EmmaWilmotUKThe effectiveness of isCGM: comparison of data from RCTs and routine-use
YarivYogevIsraelDEBATE: Should all pregnant women with diabetes take metformin during pregnancy
CON – Yariv Yogev
PRO – Denice Feig
EricZijlstraGermanyNew insulins: Foreseeable impact on diabetes therapy –
Oral Insulin